L Arzt-Gradwohl, S Annik Herzog, W Aberer, T Alfaya Arias, D Antolín-Amérigo, P Bonadonna, E Boni, A Bożek, M Chełmińska, B Ernst, N Frelih, R Gawlik, A Gelincik, T Hawranek, W Hoetzenecker, A Jiménez Blanco, K Kita, R Kendirlinan, M Košnik, K Laipold, R Lang, F Marchi, M Mauro, M Nittner-Marszalska, I Poziomkowska-Gęsicka, V Pravettoni, D Preziosi, O Quercia, N Reider, M Rosiek-Biegus, B Ruiz-Leon, C Schrautzer, P Serrano, A Sin, B Ayşe Sin, J Stoevesandt, A Trautmann, M Vachová, G Johannes Sturm
BACKGROUND AND OBJECTIVE: The safety profile of venom immunotherapy (VIT) is a relevant issue and considerable differences in safety and efficacy of VIT have been reported. The primary aim of this study was to evaluate the safety of ACE inhibitors and beta-blockers during VIT, which has already been published. For a second analysis, data concerning premedication and venom preparations in relation to systemic adverse events (AE) during the up-dosing phase and the first year of the maintenance phase were evaluated as well as the outcome of field stings and sting challenges...
November 8, 2023: Journal of Investigational Allergology & Clinical Immunology